Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011)

Celldex Therapeutics (CLDX) recorded quarterly Long-Term Debt Repayments of $12.5 million in Q1 2011.

Celldex Therapeutics (CLDX) Long-Term Debt Repayments (2011) Analysis & Trends

Celldex Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $12.5 million for Q1 2011.

In Q1 2011, Long-Term Debt Repayments changed N/A year-over-year to $12.5 million; the TTM figure through Dec 2011 stood at $12.5 million (changed N/A YoY), while the FY2020 annual figure was $3.0 million, changed N/A from the prior year.
Long-Term Debt Repayments was $12.5 million for Q1 2011 at Celldex Therapeutics.
In the past five years, Long-Term Debt Repayments ranged from a high of $12.5 million in Q1 2011 to a low of $12.5 million in Q1 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Celldex Therapeutics	2.16 Bn	2.16 Bn	-1.44 Mn	-

Download Data

Date	Value
Mar 31, 2011	12.50 Mn
Mar 31, 2011	12.50 Mn